CAM
REGN icon

Covenant Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Covenant Asset Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Hold
0
– -$2.03M – 168
2025
Q1 		– Hold
0
– – – 60
2024
Q4 		– Hold
0
– – – 53
2024
Q3 		– Hold
0
– – – 13
2024
Q2 		– Hold
0
– – – 14
2024
Q1 		– Hold
0
– – – 9
2023
Q4 		– Hold
0
– – – 8
2023
Q3 		– Hold
0
– -$2.51M – 160
2023
Q2 		– Hold
0
– – – 55
2023
Q1 		– Hold
0
– – – 54
2022
Q4 		– Hold
0
– – – 5

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Covenant Asset Management's REGN Position: Q2 2025 in Review

Covenant Asset Management sold out of Regeneron Pharmaceuticals (REGN) in Q2 2025, closing a stake of 387 shares — an estimated $245K sold.

Covenant Asset Management first reported a position in REGN in Q4 2016 and held it in 34 quarters. The position peaked at $8.1M in Q1 2022. 1,202 funds tracked by Wall St. Rank hold REGN as of Q2 2025.

  • Covenant Asset Management reported no remaining Regeneron Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Covenant Asset Management sold 387 Regeneron Pharmaceuticals shares in Q2 2025, an estimated $245K.
  • Covenant Asset Management first reported a position in Regeneron Pharmaceuticals in Q4 2016 and held it in 34 quarters.
  • Covenant Asset Management's Regeneron Pharmaceuticals position peaked at $8.1M in Q1 2022.
  • 1,202 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2025.

Based on Covenant Asset Management's 13F filing for Q2 2025, filed 17 Jul 2025.